Literature DB >> 17307985

Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.

T Norén1, T Akerlund, M Wullt, L G Burman, M Unemo.   

Abstract

In silico, we identified fusA (2,067 bp) in Clostridium difficile 630. Sequencing of fusA in posttherapy fusidic acid-resistant C. difficile isolates from 12 patients with C. difficile-associated diarrhea (CDAD) identified fusA mutations, one or two nonsynonymous substitutions, or in one case a deletion of one codon associated with resistance. Five of these mutations have previously been described in fusA of fusidic acid-resistant Staphylococcus aureus, but seven were novel fusA mutations. Fusidic acid monotherapy for CDAD seemed to rapidly select conserved resistant mutants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17307985      PMCID: PMC1855567          DOI: 10.1128/AAC.01283-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Structure of a mutant EF-G reveals domain III and possibly the fusidic acid binding site.

Authors:  M Laurberg; O Kristensen; K Martemyanov; A T Gudkov; I Nagaev; D Hughes; A Liljas
Journal:  J Mol Biol       Date:  2000-11-03       Impact factor: 5.469

2.  Fusidic acid resistance in Staphylococcus aureus isolates.

Authors:  Erwin M Brown; Paul Thomas
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

3.  E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid.

Authors:  M J Leroi; S Siarakas; T Gottlieb
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-01       Impact factor: 3.267

4.  Antimicrobial activity and mechanisms of resistance to cephalosporin P1, an antibiotic related to fusidic acid.

Authors:  A J O'Neill; J M Bostock; A Morais Moita; I Chopra
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

5.  Clonal spread among Swedish children of a Staphylococcus aureus strain resistant to fusidic acid.

Authors:  A Osterlund; T Eden; B Olsson-Liljequist; S Haeggman; G Kahlmeter
Journal:  Scand J Infect Dis       Date:  2002

6.  Genome sequence and comparative analysis of the solvent-producing bacterium Clostridium acetobutylicum.

Authors:  J Nölling; G Breton; M V Omelchenko; K S Makarova; Q Zeng; R Gibson; H M Lee; J Dubois; D Qiu; J Hitti; Y I Wolf; R L Tatusov; F Sabathe; L Doucette-Stamm; P Soucaille; M J Daly; G N Bennett; E V Koonin; D R Smith
Journal:  J Bacteriol       Date:  2001-08       Impact factor: 3.490

7.  Antibiotic susceptibility of Clostridium difficile.

Authors:  D W Burdon; J D Brown; D J Youngs; Y Arabi; N Shinagawa; J Alexander-Williams; M R Keighley; R H George
Journal:  J Antimicrob Chemother       Date:  1979-05       Impact factor: 5.790

8.  Complete genome sequence of Clostridium perfringens, an anaerobic flesh-eater.

Authors:  Tohru Shimizu; Kaori Ohtani; Hideki Hirakawa; Kenshiro Ohshima; Atsushi Yamashita; Tadayoshi Shiba; Naotake Ogasawara; Masahira Hattori; Satoru Kuhara; Hideo Hayashi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

9.  Fusidic acid cream for impetigo. Emergence of resistance to fusidic acid limits its use.

Authors:  Vivienne C Weston; Timothy C J Boswell; Roger G Finch; William Perkins
Journal:  BMJ       Date:  2002-06-08

10.  Molecular analysis of fusidic acid resistance in Staphylococcus aureus.

Authors:  Silke Besier; Albrecht Ludwig; Volker Brade; Thomas A Wichelhaus
Journal:  Mol Microbiol       Date:  2003-01       Impact factor: 3.501

View more
  7 in total

Review 1.  Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing.

Authors:  Zhong Peng; Dazhi Jin; Hyeun Bum Kim; Charles W Stratton; Bin Wu; Yi-Wei Tang; Xingmin Sun
Journal:  J Clin Microbiol       Date:  2017-04-12       Impact factor: 5.948

2.  Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1.

Authors:  Thomas Akerlund; Ingela Persson; Magnus Unemo; Torbjörn Norén; Bo Svenungsson; Marlene Wullt; Lars G Burman
Journal:  J Clin Microbiol       Date:  2008-02-20       Impact factor: 5.948

3.  Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.

Authors:  Tobias Norström; Jonas Lannergård; Diarmaid Hughes
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191

Review 4.  Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.

Authors:  Jennifer A Leeds
Journal:  Cold Spring Harb Perspect Med       Date:  2016-02-01       Impact factor: 6.915

5.  Effect of Ferredoxin Receptor FusA on the Virulence Mechanism of Pseudomonas plecoglossicida.

Authors:  Rongchao He; Jiajia Wang; Miaozhen Lin; Jing Tian; Bi Wu; Xiaohan Tan; Jianchuan Zhou; Jiachen Zhang; Qingpi Yan; Lixing Huang
Journal:  Front Cell Infect Microbiol       Date:  2022-03-22       Impact factor: 5.293

Review 6.  Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance.

Authors:  Priscilla A Johanesen; Kate E Mackin; Melanie L Hutton; Milena M Awad; Sarah Larcombe; Jacob M Amy; Dena Lyras
Journal:  Genes (Basel)       Date:  2015-12-21       Impact factor: 4.096

7.  Origin, genomic diversity and microevolution of the Clostridium difficile B1/NAP1/RT027/ST01 strain in Costa Rica, Chile, Honduras and Mexico.

Authors:  Enzo Guerrero-Araya; Claudio Meneses; Eduardo Castro-Nallar; Ana M Guzmán D; Manuel Álvarez-Lobos; Carlos Quesada-Gómez; Daniel Paredes-Sabja; César Rodríguez
Journal:  Microb Genom       Date:  2020-03-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.